Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of nemolizumab (CIM331) in hemodialysis patients with pruritus
jRCT2080222909Phase 2
- Sponsor
- Chugai Pharmaceutical Co., Ltd.
- Start
- Jul 2015
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in chronic kidney disease-associated pruritus (CKD-aP) comparing Nemolizumab with Placebo (2 arms).
02
Drugs
nemolizumab
03
Conditions
chronic kidney disease-associated pruritus (CKD-aP)
Beyond the preview
Go deeper on jRCT2080222909.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080222909.